News
FDA approves new treatment for highly drug-resistant forms of tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received U.S. approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB
